Seres Therapeutics

MCRB42

Penny Stock

$0.66arrow_drop_down4.56%-$0.03

Penny Stock

MCRB42

$0.66

arrow_drop_down4.56%-$0.03

Penny Stock

Performance History

Key Stats
Open	$0.69
Prev. Close	$0.69
EPS	-1.19
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$104.75M
PE Ratio	-

	LOW	HIGH
Day Range	0.69	0.71
52 Week Range	0.54	2.05

Ratios

Revenue	-





EPS	-1.19

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Seres Therapeutics (MCRB)

Seres Therapeutics Inc (MCRB) is a clinical-stage biotechnology company focused on developing microbiome therapeutics to treat serious diseases. Their proprietary microbiome therapeutics platform harnesses the power of the human microbiome, the collective genome of microbes living in and on the human body, to develop potentially transformative therapies. Seres Therapeutics is at the forefront of microbiome research and is dedicated to pioneering new approaches to improve human health. With a strong emphasis on scientific rigor and innovation, the company is committed to advancing the field of microbiome therapeutics.

Seres Therapeutics Inc (MCRB) stock has experienced fluctuations in its price history. Investors interested in tracking the company's stock performance can check the latest stock quote for MCRB. The company's stock news and analysis provide valuable insights into market trends and investor sentiment. Understanding the market cap of Seres Therapeutics Inc (MCRB) is also important for investors, as it provides an indication of the company's overall value. Additionally, comparing Seres Therapeutics Inc (MCRB) to its industry peers can help investors gauge its performance.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Eric D. Shaff M.B.A.
Headquarters: Cambridge
Employees: 431
Exchange: NASDAQ

Keep an eye on Seres Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Seres Therapeutics 's (MCRB) price per share?

The current price per share for Seres Therapeutics (MCRB) is $0.66. The stock has seen a price change of -$0.03 recently, indicating a -4.57% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Seres Therapeutics (MCRB)?

For Seres Therapeutics (MCRB), the 52-week high is $2.05, which is 208.78% from the current price. The 52-week low is $0.54, the current price is 22.94% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Seres Therapeutics (MCRB) a growth stock?

Seres Therapeutics (MCRB) has shown an average price growth of -3.67% over the past three years. It has received a score of 6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Seres Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Seres Therapeutics (MCRB) stock price performance year to date (YTD)?

As of the latest data, Seres Therapeutics (MCRB) has a year-to-date price change of -52.58%. Over the past month, the stock has experienced a price change of -20.58%. Over the last three months, the change has been -25.4%. Over the past six months, the figure is -31.21%. Looking at a longer horizon, the five-year price change stands at -81.91%.

help

Is Seres Therapeutics (MCRB) a profitable company?

Seres Therapeutics (MCRB) has a net income of -$113.72M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.04% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -42.21K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $111.21M. Operating income is noted at -$107.28M. Furthermore, the EBITDA is -$151.58M.

help

What is the market capitalization of Seres Therapeutics (MCRB)?

Seres Therapeutics (MCRB) has a market capitalization of $100.55M. The average daily trading volume is 0.66, indicating the stock's liquidity and investor engagement.